Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Anterior chamber retrievable mattress sutures (ARMS) in the management of DMEK graft in aniridic patients

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cornea I

Venue: Poster Village: Pod 3

First Author: : S.Stéphan FRANCE

Co Author(s): :    D. Guindolet   E. Gabison           

Abstract Details

Purpose:

To report a new surgical technique for graft positioning during descemet’s membrane endothelial keratoplasty (DMEK) in a patient with irian stromal atrophy using intracamerular “in-and–out” retrievable sutures : Anterior chamber Retrievable Mattress Sutures (ARMS).

Setting:

Department of Ophtalmology, Fondation ophtalmologique A. de Rothschild, 25 rue Manin , 75019 Paris

Methods:

A 54-year-old woman with unilateral iridocorneal endothelial syndrome and well-controlled intra-ocular pressure, presented a corneal edema. DMEK combined with phakoemulsification were performed using peroperative optic coherence tomography(OCT). To manage iris atrophy which is associated with a high risk of peroperative graft dislodgment, three temporary crossed sutures were placed into the anterior chamber, resulting in a new iris plan to maintain graft position against the cornea and to avoid graft displacement into the posterior chamber. Before intracamerular air bubble injection, ARMS were lifted allowing a better management of the air bubble positionning. The sutures were retrieved at the end.

Results:

Mean corrected visual acuity was counting fingers preoperatively and 9/10e one month after surgery. Pachymetry was 562 micrometers at 1 months.

Conclusions:

The use of ARMS during DMEK creates a temporary iris-plane in patients presenting iris stromal atrophy. This technique could thus be a problem solving tool to facilitate optimal graft position in the absence of normal iris-plane.

Financial Disclosure:

NONE

Back to previous